Hippocratic AI
Vertical AI (legal, health, finance) · https://www.hippocraticai.com
Verdict: Hold · Confidence: medium · Reviewed 2026-10-15
Hippocratic AI sells non-diagnostic patient-facing healthcare agents. It closed a $126 million Series C at a $3.5 billion valuation on November 3, 2025, bringing total funding to $404 million. It names more than 50 health systems, payors, and pharma clients and says it has completed over 115 million clinical interactions. Revenue is not disclosed.
Rubric
| Dimension | Score (1–5) | Notes & sources |
|---|---|---|
| Real customers & revenue quality Are there named paying customers, recurring revenue, and retention evidence? | 3/5 | The company says it has partnerships with over 50 large health systems, payors, and pharma clients in 6 countries, over 1,000 clinical use cases, and over 115 million clinical patient interactions, plus payors representing over 5 of the top 10. Named systems include Cleveland Clinic, Northwestern Medicine, and Cincinnati Children's. No revenue figure was on the release.
|
| Unit economics Do gross margins survive inference/compute costs? Is pricing durable? | Unknown | Unknown — no public figure found. |
| Moat Proprietary data, distribution, switching costs, or tech that is hard to copy? | 3/5 | The company limits agents to non-diagnostic tasks and markets a Polaris safety architecture, with health systems as both customers and investors. Safety claims are company-reported, including 'no safety issues' across 115 million interactions.
|
| Platform risk Could a model provider or incumbent ship this as a feature? (higher score = lower risk) | 3/5 | Agents sit on generative models and on health-system workflows Hippocratic does not own. A buyer is exposed to clinical-safety failures and to larger EHR or payer platforms bundling similar outreach agents.
|
| Team & execution Shipping cadence, leadership track record, stability. | 4/5 | Munjal Shah is CEO. General Catalyst says it co-created the company. The Series C added Avenir, CapitalG, UHS, and Cincinnati Children's on top of a16z, Kleiner Perkins, and Premji, after the company said it commercialized only 15 months earlier.
|
| Funding vs. traction Is capital raised justified by verifiable traction? | 2/5 | $404 million raised and a $3.5 billion valuation are public. Revenue is not. Interaction volume shows usage, not that the price covers inference and services.
|
| Hype signals Demo-driven marketing, vague metrics, valuation outrunning evidence? (higher score = fewer red flags) | 2/5 | The release calls the agents the safest and says 115 million interactions had no safety issues, without an independent audit in the post. The valuation is high relative to undisclosed revenue.
|
Listing source: https://www.hippocraticai.com. Revenue, users, and valuation figures appear only when publicly sourced; otherwise they are marked unknown.